Abeona Therapeutics (ABEO)
(Delayed Data from NSDQ)
$4.95 USD
-0.03 (-0.60%)
Updated Aug 14, 2024 03:59 PM ET
After-Market: $4.94 -0.01 (-0.20%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Abeona Therapeutics Inc. [ABEO]
Reports for Purchase
Showing records 21 - 40 ( 89 total )
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
EB-101 Pivotal Program Successful FDA Type B Meeting; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
VIITAL Study Initiated; Intellectual Property Estate Broadened; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Financing Completed; Runway Lengthened; Reducing Target to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
VIITAL Pivotal Trial Program Cleared to Proceed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Awaiting Final Pivotal Program Clearance; 3Q19 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Positive Long-Term EB-101 Data Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Financial Results Reported; EB-101 Pivotal Trial Initiation Approaching; Lowering Target to $15 Ahead of Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
ABO-102 Interim Data Appear Positive; EB-101 Pivotal Program Timeline Updated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
ABO-202 Fast Track Designation Granted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Gene Therapy Pricing Paradigm Emerges; EB-101 Program Continues Progress; Reiterate Buy; Modulating Target to $23
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Retinal Disease Therapeutic Potential Showcased at ARVO Meeting; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
New Preclinical Data Herald Potential in Cystic Fibrosis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
ABO-101 Fast Track Designation Received; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Brammer Bio Acquisition Underscores Gene Therapy Strategic Interest; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2018 Financial Results Reported; Multiple Clinical Catalysts Ahead; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
M-A Rife in Gene Therapy Sector; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Permanent Chief Executive Appointment; New Supportive Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
R-D Day Highlights Pipeline Depth; EB-101 Entering Pivotal Testing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Celenex Acquisition Underscores Gene Therapy Asset Value; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R